Home › Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3...
 

Keywords :   


Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3...

2014-11-05 13:20:10| Biotech - Topix.net

Amgen today announced the top-line secondary endpoint results of overall survival from the Phase 3 TRINOVA-1 trial in women with recurrent platinum-resistant ovarian cancer. The study, which evaluated trebananib plus paclitaxel versus placebo plus paclitaxel, did not demonstrate a statistically significant improvement in overall survival.

Tags: results phase secondary announces

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
08.05Beef Australia signs MOU with Canadian Western Agribition
08.05Sheboygan Paint Company Announces Promotion
08.05Space-age farm technology wins Beef2024 pitching contest
08.05American Cleaning Institutes Mid-Year Meeting is June 10-12
08.05Procter & Gamble Recognizes Key Suppliers
08.05Q1 2024 Net Revenue Up 28% for Oddity
08.05INX issues 2023 Sustainability Report
08.05Precision Textiles Elevates Mattress Safety and Comfort
More »